Microtech, a wholly owned subsidiary of Medinol Inc. and a leader in global medtech research and development, announced that it has begun human clinical trials of its microsensor platform in a study to measure atrial pressure, which is used for treating heart failure is important. The first implantation was recently performed by Prof. Erez Sharoni at Beilinson Medical Center in Petah-Tikva, Israel.
Microtech’s implantable microsensor platform is the culmination of decades of development of a new class of sensor technology that can not only be used as a standalone device, but can also be integrated into any existing device. Due to its submillimeter size, completely passive function and external communication via ultrasound, this technology makes it possible to transform existing implants into intelligent devices capable of collecting data and performing multiple functions at the same time.
Prof. Sharoni, Head of Cardiothoracic Surgery, said of Microtech’s promising sensor platform: “This amazing technology could change the standard of care for patients with heart failure, particularly, as in this study, those receiving LVADs or heart transplants .”
The data generated by the implanted sensors will be collected and used by heart failure specialists to support clinical decision making for these patients. “Heart failure is characterized by periods of quiescence followed by periods of deterioration requiring repeated hospitalizations. This groundbreaking technology will allow us to track patients’ parameters in real time, intervene earlier if necessary, and reduce the morbidity and mortality of these patients reduce,” said Dr. Tuvia Ben-Gal, head of the heart failure department at Rabin Medical Center.
“Integrating sensors into existing medical devices gives physicians the ability to treat patients based on quantifiable physiological parameters rather than symptoms and is a critical step toward improving access to equitable healthcare across the global community. With a compact With a home device, a patient with a Microtech-enabled implant can provide instant, highly accurate pressure readings directly to their doctor, eliminating geographical distances or mobility issues,” says Dr. Yoram Richter, CEO of Medinol. “This unique capability is important for a wide range of clinical scenarios, including patients with heart failure, glaucoma, hydrocephalus, portal hypertension, AAA endoleaks and many others, enabling broader access to healthcare and fewer doctor/hospital visits. From the standpoint of From the perspective of treating physicians and device manufacturers, what is most important is that sensor-based smart devices go beyond acute anatomical corrections and extend treatment into lifelong patient care.
About Medinol
At Medinol, we strive to create a paradigm shift in the diagnosis and treatment of disease. Whether it’s developing state-of-the-art devices for stenting in different areas of the body, dramatically reducing complications during structural heart procedures, or providing real-time insights into the human body’s physiological metrics through implantable sensors, we evaluate current technology and boldly reimagine the procedures and look years into the future to develop new devices that expand the reach of physicians both physically and geographically. In collaboration with our partners from medicine and industry, Medinol is already shaping the future today.
For more information, see www.medinol.com or contact Jeff Roach, Chief Commercial Officer at JeffR@medinol.com.
Logo – https://mma.prnewswire.com/media/1894777/Medinol_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/microtech-meldet-ersten-fall-von-implantierbarem-mikrosensor-gegen-herzinsuffizienz-beim-menschen-302339071.html